GE HealthCare Shares Drop 7.82% Despite 3% Revenue Growth and 164.4% Volume Surge to 930M Ranking 113th in Daily Trading Activity as Full-Year Guidance Raised

On July 30, 2025, General Electric’s GE HealthCare (GEHC) closed with a 7.82% decline, despite reporting a 3% year-over-year revenue increase to $5 billion in Q2 2025. Trading volume surged 164.4% to $930 million, ranking GE 113th in daily trading activity. The company raised full-year guidance, citing strong capital equipment demand and operational efficiency gains.

GE HealthCare’s adjusted EPS rose to $1.06, driven by lower tax and interest expenses. Segment performance highlighted a 14% growth in pharmaceutical diagnostics revenue, though Imaging and Patient Care Solutions saw marginal gains. CEO Peter Arduini emphasized progress in tariff mitigation and AI-enabled medical devices, including expanded FDA approvals for radiopharmaceuticals. Strategic collaborations and product innovations, such as AI-powered imaging tools, were cited as growth drivers.

The firm’s cash flow improved significantly, with operating cash flow at $94 million and free cash flow at $7 million, up from negative figures in the prior year. However, adjusted EBIT margin dipped to 14.6% due to tariff pressures, offset by productivity gains. Full-year guidance now anticipates 3% organic revenue growth and $4.43–$4.63 adjusted EPS, incorporating a reduced tariff impact of $0.45.

A backtest of a strategy buying the top 500 high-volume stocks daily from 2022 to July 30, 2025, delivered a 166.71% return, outperforming the benchmark’s 29.18% by 137.53%. The strategy’s compound annual growth rate (CAGR) of 31.89% underscored its effectiveness in leveraging liquidity and market sentiment for short-term gains across diverse equities.